TICKERNERD
Menu
FBLGFBLGHealthcare · Biotechnology

FBLG Stock Forecast: FibroBiologics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.93
+0.22% on the day

The 2 Wall Street analysts covering FibroBiologics, Inc. hold a median 12-month price target of $13 — +1244.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$6.6M
Ticker Nerd rank
42/ 100
Median analyst target
$13
Analysts covering
2
Revenue$0.0
Operating income−$4.0M
Net income−$4.1M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.1%
1M
−28.5%
YTD
−79.3%
1Y
−88.3%
From 52W high
−89.3%
From 52W low
+48.3%
$0.63
$8.70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FBLG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores FibroBiologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Accruals
76
Issuance
63
Revisions
56
Volatility
49
Growth
47
Momentum
17
Value
17
Quality
14

Size (93): Smaller than most of the companies we track.

Quality (14): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FBLG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBLG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26FBLGHigh $19Median $13Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $6Median $13High $19

The green dot is the last close — the median target sits +1244.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Aug 2026HC Wainwright & Co.MaintainsBuy—
4 Aug 2026HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
4 May 2026Maxim GroupDowngradeHold—
4 May 2026Maxim GroupDowngradeHold—
16 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026D. Boral CapitalDowngradeHold—
12 Mar 2026D. Boral CapitalMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
2 Jan 2026HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
5 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Nov 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025HC Wainwright & Co.MaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

FBLG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FBLG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, FibroBiologics, Inc. returned −88.3% against +12.4% for the S&P 500, dividends included.

FBLG vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26FBLGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FBLG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

FibroBiologics, Inc. (FBLG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
1.2×

Cheaper than 63% of US stocks

EV / EBITDA
−0.3×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−660.1%

Higher than 2% of US stocks

Return on assets
−95.8%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

FibroBiologics, Inc. (FBLG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • FibroBiologics, Inc. has a market value of $6.6M and an enterprise value of $4.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.8M.

  • Shares outstanding: 6.1M.

  • Trailing P/E: −0.1×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • FibroBiologics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

FBLG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBLGFibroBiologics, Inc.$6.6M42
AIMAIM ImmunoTech, Inc.$6.1M21
APREAprea Therapeutics, Inc.$6.0M44
ENVBEnveric Biosciences, Inc.$6.4M18
XCURExicure, Inc.$6.4M53
ALZNAlzamend Neuro, Inc.$5.8M27
ACXPAcurx Pharmaceuticals, Inc.$5.8M25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own FibroBiologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FBLG news & analysis

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

PRNewsWire · 19 Oct 2026positive

FibroBiologics presented preclinical data on its fibroblast spheroid-derived chondrocyte (FSdC) spheroids for degenerative disc disease at the North American Spine Society 2026 Annual Meeting. In a 12-week rabbit model, the spheroids preserved disc height better than the other fibroblast-based approaches tested.

Why it matters — The presentation reports a comparative preclinical result for a FibroBiologics candidate targeting degenerative disc disease.

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

PRNewsWire · 14 Oct 2026positive

FibroBiologics announced that IP Australia issued a Notice of Acceptance for Australian Patent Application No. 2024200985. The application covers methods combining fibroblasts, platelet-rich plasma, and nucleus pulposus conditioned media to regenerate cartilage cells and improve the condition of degenerated and aged discs.

Why it matters — The acceptance marks progress in the company’s patent portfolio for a cellular blend aimed at cartilage regeneration in degenerated spinal discs.

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

PRNewsWire · 7 Oct 2026positive

FibroBiologics filed a U.S. patent application for a cell-based technology designed to produce GLP-1, GIP and GLP-2 continuously inside the body. The company described it as an alternative approach to regular injections or daily pills.

Why it matters — The filing relates to a potential peptide-delivery approach in FibroBiologics’ therapeutic development portfolio.

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

PRNewsWire · 29 Sept 2026positive

FibroBiologics announced that the European Patent Office has granted European Patent No. covering methods of enhancing fibroblast therapeutic activity, specifically augmenting regenerative efficacy using platelet rich plasma and cytokines, with claims directed to angiogenesis and spinal disc regeneration. The company is a clinical-stage biotechnology firm focused on fibroblast-based therapeutics.

Why it matters — A granted European patent strengthens FibroBiologics' intellectual property portfolio in key regenerative medicine areas, which is relevant to the company's development prospects.

FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript

Seeking Alpha · 22 Sept 2026neutral

FibroBiologics discussed its strategy and clinical progress in fibroblast-based cell therapies for chronic diseases, as captured in a Seeking Alpha transcript of the company's presentation or call.

Why it matters — A FibroBiologics watcher would care because this transcript offers insight into the company's planned direction and the status of its clinical development pipeline.

FAQ

Frequently asked questions about FBLG stock

What is the FBLG stock price forecast for 2026-2027?

The 2 Wall Street analysts covering FibroBiologics, Inc. have a median 12-month price target of $13, with estimates ranging from $6 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBLG stock a buy right now?

Of the 2 analysts covering FibroBiologics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks FibroBiologics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBLG?

As at 31 Oct 2026, FibroBiologics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will FBLG stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1244.1% from the last close, and Ticker Nerd's factor model ranks FibroBiologics, Inc. 42 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBLG stock forecast for 2030?

No analyst covering FibroBiologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $19 over the next 12 months.

How has FBLG stock performed over the past year?

FibroBiologics, Inc. returned -88.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does FibroBiologics, Inc. do?

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases.

What is the latest news on FBLG?

The most recent item we track (PRNewsWire, 19 Oct 2026): "FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting". FibroBiologics presented preclinical data on its fibroblast spheroid-derived chondrocyte (FSdC) spheroids for degenerative disc disease at the North American Spine Society 2026 Annual Meeting. In a 12-week rabbit model, the spheroids preserved disc height better than the other fibroblast-based approaches tested.

Company

About FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company’s pipeline includes product candidates such as CYWC628, CYMS101, CYPS317, and CybroCell, which are being developed to address areas of significant unmet medical need. FibroBiologics also works with fibroblast cells and fibroblast-derived materials in research programs related to tissue regeneration and immune modulation. Based in Houston, Texas, FibroBiologics plays a specialized role in the biotechnology market by advancing cell-based approaches designed for therapeutic use across several disease areas.

CEO Mr. Peter O'Heeron · 15 employees · United States · https://fibrobiologics.com